Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $4.6 million.

  • Karyopharm Therapeutics' Other Accumulated Expenses fell 333.19% to $4.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.6 million, marking a year-over-year decrease of 333.19%. This contributed to the annual value of $4.6 million for FY2025, which is 333.19% down from last year.
  • According to the latest figures from Q4 2025, Karyopharm Therapeutics' Other Accumulated Expenses is $4.6 million, which was down 333.19% from $1.8 million recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' Other Accumulated Expenses ranged from a high of $7.6 million in Q4 2021 and a low of $524000.0 during Q2 2021
  • Its 5-year average for Other Accumulated Expenses is $2.9 million, with a median of $2.0 million in 2024.
  • Per our database at Business Quant, Karyopharm Therapeutics' Other Accumulated Expenses soared by 25591.6% in 2022 and then tumbled by 3300.58% in 2024.
  • Karyopharm Therapeutics' Other Accumulated Expenses (Quarter) stood at $7.6 million in 2021, then decreased by 15.96% to $6.4 million in 2022, then increased by 11.18% to $7.1 million in 2023, then plummeted by 33.01% to $4.8 million in 2024, then decreased by 3.33% to $4.6 million in 2025.
  • Its last three reported values are $4.6 million in Q4 2025, $1.8 million for Q3 2025, and $1.6 million during Q2 2025.